Search

Your search keyword '"Gottlieb PA"' showing total 238 results

Search Constraints

Start Over You searched for: Author "Gottlieb PA" Remove constraint Author: "Gottlieb PA"
238 results on '"Gottlieb PA"'

Search Results

1. Defining Pathways forDevelopment of Disease-Modifying Therapies in Children With Type 1 Diabetes: A Consensus Report

2. Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: Metabolic and immunologic features at baseline identify a subgroup of responders

4. B-lymphocyte depletion with rituximab and β-cell function: Two-year results

5. Costimulation modulation with abatacept in patients with recent-onset type 1 diabetes: Follow-up 1 year aftercessation of treatment

6. Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial

7. Fall in C-peptide during first 2 years from diagnosis: Evidence of at least two distinct phases from composite type 1 diabetes trialnet data

8. Simplifying prediction of disease progression in pre-symptomatic type 1 diabetes using a single blood sample

9. Stability of human rapamycin-expanded CD4+CD25+ T regulatory cells

10. Understanding and preventing type 1 diabetes through the unique working model of TrialNet

14. Dysregulated Toll-like receptor-induced interleukin-1β and interleukin-6 responses in subjects at risk for the development of type 1 diabetes.

15. Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite Type 1 Diabetes TrialNet data.

17. Failure to preserve beta-cell function with mycophenolate mofetil and daclizumab combined therapy in patients with new- onset type 1 diabetes.

21. Identification and characterization of Smyd2: a split SET/MYND domain-containing histone H3 lysine 36-specific methyltransferase that interacts with the Sin3 histone deacetylase complex

24. Islet-antigen reactive B cells display a unique phenotype and BCR repertoire in autoantibody positive and recent-onset type 1 diabetes patients.

25. Early Metabolic Endpoints Identify Persistent Treatment Efficacy in Recent-Onset Type 1 Diabetes Immunotherapy Trials.

26. Genetic Associations with C-peptide Levels before Type 1 Diabetes Diagnosis in At-Risk Relatives.

27. An Insulin-Chromogranin A Hybrid Peptide Activates DR11-Restricted T Cells in Human Type 1 Diabetes.

28. Lower Prevalence of Diabetic Ketoacidosis at Diagnosis in Research Participants Monitored for Hyperglycemia.

29. C-peptide and metabolic outcomes in trials of disease modifying therapy in new-onset type 1 diabetes: an individual participant meta-analysis.

30. Utility and precision evidence of technology in the treatment of type 1 diabetes: a systematic review.

31. Teplizumab: A Disease-Modifying Therapy for Type 1 Diabetes That Preserves β-Cell Function.

32. Second international consensus report on gaps and opportunities for the clinical translation of precision diabetes medicine.

33. Identification of an anergic BND cell-derived activated B cell population (BND2) in young-onset type 1 diabetes patients.

34. Abatacept for Delay of Type 1 Diabetes Progression in Stage 1 Relatives at Risk: A Randomized, Double-Masked, Controlled Trial.

35. Barriers to Screening: An Analysis of Factors Impacting Screening for Type 1 Diabetes Prevention Trials.

36. Temporal development of T cell receptor repertoires during childhood in health and disease.

37. Mechano-Sensing Channel PIEZO2 Enhances Invasive Phenotype in Triple-Negative Breast Cancer.

38. Association of High-Affinity Autoantibodies With Type 1 Diabetes High-Risk HLA Haplotypes.

39. Peripheral immunophenotyping of AITD subjects reveals alterations in immune cells in pediatric vs adult-onset AITD.

40. Simplifying prediction of disease progression in pre-symptomatic type 1 diabetes using a single blood sample.

41. Imatinib therapy for patients with recent-onset type 1 diabetes: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.

42. Low-Dose ATG/GCSF in Established Type 1 Diabetes: A Five-Year Follow-up Report.

43. T-cell responses to hybrid insulin peptides prior to type 1 diabetes development.

45. Exenatide extended release in patients with type 1 diabetes with and without residual insulin production.

46. Disruption of membrane cholesterol organization impairs the activity of PIEZO1 channel clusters.

47. Endotypes in T1D: B lymphocytes and early onset.

48. Risk of Islet and Celiac Autoimmunity in Cotwins of Probands With Type 1 Diabetes.

49. Clinical trial data validate the C-peptide estimate model in type 1 diabetes.

50. Introducing the Endotype Concept to Address the Challenge of Disease Heterogeneity in Type 1 Diabetes.

Catalog

Books, media, physical & digital resources